• Stoke Therapeutics disclosed new long-term clinical data for zorevunersen in Dravet syndrome ahead of presentations at the European Epilepsy Congress.
• Results will be presented Sept. 6-8 in Athens, including the first medical meeting disclosure of 4-year outcomes from open-label extension studies.
• Data showed sustained improvements in cognition and behavior, durable seizure reductions, improved quality of life, supportive of disease-modifying potential.
• Safety remained broadly consistent, with frequent CSF protein elevations reported without serious clinical complications or hydrocephalus.
• A global Phase 3 EMPEROR trial is underway, with top-line results expected in Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260901006975) on September 01, 2026, and is solely responsible for the information contained therein.